Abstract
Benzimidazole derivatives 1-24 have been synthesized and their in vitro β-glucuronidase inhibitory activitiy was evaluated. Compounds 15 (IC50 = 6.33 ± 0.40 µM), 7 (IC50 = 22.0 ± 0.33 µM), 2 (IC50 = 23.1 ± 1.78 µM), 17 (IC50 = 23.9 ± 1.46 µM), and 3 (IC50 = 33.8 ± 1.61 µM) showed more potent β-glucuronidase inhibitory activity than the standard (D-saccharic acid 1,4 lactone, IC50 = 48.4 ± 1.25 µM). This study has identified a new series of potential β-glucuronidase inhibitors. A structure-activity relationship has also been studied.
Keywords: Benzimidazole, β-glucuronidase inhibition, glucuronosyl-O-bonds, antihelmintic, anticoagulant, leukaemia, antihistaminic, antihypertensive, dimethylformamide, lepromatous
Medicinal Chemistry
Title:Synthesis and β-Glucuronidase Inhibitory Potential of Benzimidazole Derivatives
Volume: 8 Issue: 3
Author(s): Khalid Mohammed Khan, Momin Khan, Nida Ambreen, Fazal Rahim, Shagufta Naureen, Shahnaz Perveen, M. Iqbal Choudhary and Wolfgang Voelter
Affiliation:
Keywords: Benzimidazole, β-glucuronidase inhibition, glucuronosyl-O-bonds, antihelmintic, anticoagulant, leukaemia, antihistaminic, antihypertensive, dimethylformamide, lepromatous
Abstract: Benzimidazole derivatives 1-24 have been synthesized and their in vitro β-glucuronidase inhibitory activitiy was evaluated. Compounds 15 (IC50 = 6.33 ± 0.40 µM), 7 (IC50 = 22.0 ± 0.33 µM), 2 (IC50 = 23.1 ± 1.78 µM), 17 (IC50 = 23.9 ± 1.46 µM), and 3 (IC50 = 33.8 ± 1.61 µM) showed more potent β-glucuronidase inhibitory activity than the standard (D-saccharic acid 1,4 lactone, IC50 = 48.4 ± 1.25 µM). This study has identified a new series of potential β-glucuronidase inhibitors. A structure-activity relationship has also been studied.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Khan Momin, Ambreen Nida, Rahim Fazal, Naureen Shagufta, Perveen Shahnaz, Iqbal Choudhary M. and Voelter Wolfgang, Synthesis and β-Glucuronidase Inhibitory Potential of Benzimidazole Derivatives, Medicinal Chemistry 2012; 8 (3) . https://dx.doi.org/10.2174/1573406411208030421
DOI https://dx.doi.org/10.2174/1573406411208030421 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Immunotoxins and Other Conjugates: Pre-clinical Studies
Mini-Reviews in Medicinal Chemistry Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Anti-Cancer Agents in Medicinal Chemistry circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma
Current Cancer Drug Targets Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Direct Gene Expression Analysis
Current Pharmaceutical Biotechnology Improving Safety of Gene Therapy
Current Drug Safety Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology Pin1: A New Outlook in Alzheimers Disease
Current Alzheimer Research Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease
Current Pharmaceutical Design Sphere Formation Assay is not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line
Current Stem Cell Research & Therapy MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters